Finance entity
Every one of those 1 sits in a single category, regulation. CalMatters is most often covered alongside California Institute for Immunology and Immunotherapy, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.3 for the same window.
Last mentioned: 3h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, regulation. CalMatters is most often covered alongside California Institute for Immunology and Immunotherapy, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.3 for the same window. Their average consequence score of 5 runs below the beat's 5.6 for that window. CalMatters appears in 1 tracked Finance story from August 23, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CalMatters. Shared-story counts are live from our verified record — not editorial picks.
Editorial boards argue Proposition 38's $8.4 billion bond repayment hinges on an untested 10% revenue share from future drug commercialization. Fiscal analysts may see taxpayer risk and a weak case for public borrowing when private capital could fund the research.
Source: sgvtribune.com · dailynews.com
CalMatters is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
